Bixink Therapeutics

Overview

BIXINK Therapeutics is a South Korean venture capital firm specializing in early-stage investments within the biotechnology and healthcare sectors. The firm focuses on identifying and supporting innovative companies that are developing cutting-edge treatments and technologies. By leveraging its expertise and network, BIXINK aims to foster the growth of promising startups in these industries. The firm's investment strategy encompasses a broad range of stages, including Seed, Early Stage, Series A, Series B, Growth, Late Stage, and Pre-IPO. This approach allows BIXINK to provide tailored support to companies at various points in their development, from initial concept to market readiness. The geographical focus of BIXINK spans multiple countries, including South Korea, the United States, China, Japan, Germany, France, the United Kingdom, Switzerland, Canada, Belgium, the Netherlands, Luxembourg, Finland, Austria, Poland, Denmark, Portugal, Sweden, Norway, and Italy. This extensive reach enables the firm to tap into diverse markets and identify global opportunities. BIXINK Therapeutics has a diverse portfolio of industries, reflecting its commitment to advancing various facets of the healthcare and biotechnology sectors. These include Biotechnology, Healthcare, Pharmaceuticals, Digital Therapeutics, Oncology, Mental Health, Medical Devices, Diagnostics, Medical Research, Biopharmaceuticals, Medical Technology, Clinical Trials, Regulatory Affairs, Health IT, and Medical Consulting. The firm's investment sizes range from $8.5 million to $38 million, indicating a capacity to support both emerging and more established companies in their growth trajectories.